Clinical Trials Browser

Phase 3 × Completed × exemestane × Clear all

NCT00893061 2026-03-17

MNEMOSYNE

Phase 3 Completed

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT00066690 2026-02-06

SOFT

Phase 3 Completed

3,066 enrolled 15 charts

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

Phase 3 Completed

2,672 enrolled 14 charts

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 3 Completed

622 enrolled 18 charts

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT00066573 2023-08-25

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Phase 3 Completed

7,576 enrolled 10 charts

Breast Neoplasms

NCT00083174 2023-08-25

ExCel

Phase 3 Completed

4,560 enrolled 16 charts

Breast Neoplasms

NCT02482753 2022-01-12

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT02511639 2020-12-03

MAIN-A

Phase 3 Completed

Breast Cancer Metastatic

NCT03176238 2020-04-07

EVEREXES

Phase 3 Completed

235 enrolled 11 charts

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Phase 3 Completed

Breast Neoplasms

NCT01638247 2018-09-19

MALE

Phase 3 Completed

Breast Neoplasms, Male

NCT00863655 2017-05-02

BOLERO-2

Phase 3 Completed

724 enrolled 20 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

Phase 3 Completed

Breast Neoplasms

NCT00659373 2016-07-25

Co-SOFT

Phase 3 Completed

86 enrolled 4 charts

Breast Neoplasms, Fatigue, Sleep Wake Disorders

NCT00036270 2015-10-28

TEAM

Phase 3 Completed

9,779 enrolled 13 charts

Breast Neoplasms

NCT00065325 2015-02-24

EFECT

Phase 3 Completed

Breast Neoplasms

NCT00038467 2014-05-07

IES

Phase 3 Completed

4,740 enrolled 31 charts

Breast Neoplasms

NCT00032136 2013-08-02

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002777 2012-07-02

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00143390 2012-01-25

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Phase 3 Completed

298 enrolled 13 charts

Breast Neoplasms

NCT00279448 2011-12-23

TEAM

Phase 3 Completed

Breast Neoplasms

NCT00944918 2011-08-29

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Phase 3 Completed

Breast Neoplasms

NCT00525096 2011-06-30

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT01237327 2011-05-06

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Phase 3 Completed

84 enrolled 12 charts

Breast Neoplasms

NCT00016432 2011-04-19

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Phase 3 Completed

Breast Neoplasms